Skip to main content
. 2017 Nov 24;30(2):111–117. doi: 10.1007/s40520-017-0861-1

Table 1.

Symptom outcomes for patented crystalline glucosamine sulfate (pCGS) formulation after 6 months to 3 years of treatment for knee osteoarthritis.

Table adapted from Reginster [23]

Outcome Fixed-model effect size (95% CI)a
WOMAC scale
 Total 0.33 (0.17–0.49)
 Pain 0.27 (0.12–0.43)
 Function 0.33 (0.17–0.48)
 Lequesne indexb 0.38 (0.19–0.57)

aPooled effect size: estimates and 95% CIs from fixed-model meta-analysis method using the pooled standard deviation in each study/outcome [2628]

bNot assessed in one study [27]. Heterogeneity, I 2 = 0.00